William R. LaRue

William R. LaRue has more than 25 years of experience in corporate leadership and growth strategies. As senior vice president and chief financial officer at Cadence Pharmaceuticals, Mr. LaRue oversaw the raising of more than $350 million in equity and debt and led the company through its initial public offering (IPO) in 2006 and acquisition by Mallinckrodt plc in 2014 for $1.4 billion. Mr. LaRue also served on the board of directors at Cadence, and he is currently on the board of directors of TRACON Pharmaceuticals, Inc., focused on targeted therapies for cancer and macular degeneration, and Neurelis, Inc., a private early-stage company developing product candidates for epilepsy and additional central nervous system disorders. Mr. LaRue also served as senior vice president and chief financial officer for CancerVax Corporation and was vice president and treasurer of Safeskin Corporation as well as a key member of Safeskin’s negotiating team for its acquisition by Kimberly-Clark Corporation.